Citigroup Downgrades Bio-Techne to Hold, Sets $73 Price Target

On June 29, 2026, Citigroup analyst Patrick Donnelly downgraded Bio-Techne Corporation (NasdaqGS: TECH) to a hold rating, setting a price target of $73. Shares of Bio-Techne traded near $71 on Monday.

Bio-Techne Corporation Stock Down 2.3%

Shares of Bio-Techne Corporation, listed on the NasdaqGS under the ticker TECH, traded around $71 on Monday. The company has a market capitalization of approximately $11.06 billion. It sports a P/E ratio of 101.4 and a forward P/E of 34.7, indicating high expectations for future earnings growth. The stock's beta is 1.358, suggesting it is more volatile than the broader market. Over the past year, Bio-Techne's stock has ranged from a low of $43.2 to a high of $72.16. The company's 50-day moving average is $53.02, while the 200-day moving average stands at $57.70. Bio-Techne maintains a strong liquidity position with a current ratio of 4.49 and a quick ratio of 2.80, alongside a debt-to-equity ratio of 13.92.

Recent Earnings

Bio-Techne reported revenues of about $1.21 billion, though it experienced a slight revenue contraction of 1.5%. The company's earnings per share (EPS) stood at $0.70, with a net margin of 9.05% and a return on equity (ROE) of 5.34%. Investors can look forward to the next earnings release on August 5, 2026.

Dividend

Bio-Techne pays an annual dividend rate of $0.32, which yields approximately 0.45%. The dividend payout ratio is 45.71%, indicating a balanced approach to returning profits to shareholders while retaining earnings for growth.

Insider Buying and Selling at Bio-Techne Corporation

Recent insider transactions at Bio-Techne include activity from Steven Crouse, President of Diagnostics and Spatial Biology, who sold 600 shares on June 2, 2026, without a specified price. On the same day, Crouse also bought 600 shares. Another insider, Amy Herr, bought 6,636 shares at a price of $47.60 on May 8, 2026, and subsequently sold the same amount at $48.28.

Analysts Set New Price Targets

On June 29, 2026, Citigroup's Patrick Donnelly downgraded Bio-Techne to a hold rating, setting a price target of $73. Previously, Stephens & Co. also downgraded the stock to hold with the same price target on June 26, 2026. Baird maintained its hold rating with a $73 target on the same date. Piper Sandler initiated coverage with a hold rating and a $65 target on June 11, 2026. The consensus among analysts remains a buy, with a mean target price of $67.92 based on 13 opinions.

About Bio-Techne Corporation

Bio-Techne Corporation, headquartered in Minneapolis, Minnesota, develops and sells life science reagents, instruments, and services worldwide. Operating in the healthcare sector, the company focuses on biotechnology markets through its two segments: Protein Sciences and Diagnostics and Spatial Biology. Bio-Techne offers a wide range of products, including cytokines, antibodies, and diagnostic assays, catering to research, diagnostics, and bioprocessing needs. Led by CEO Mr. Kim Kelderman, the company employs around 3,100 people.

Bottom Line

Citigroup's recent downgrade of Bio-Techne to a hold rating reflects a cautious stance amid current market conditions. Investors looking at Bio-Techne should consider the company's strong market position and financial metrics. It's important to remember that analyst ratings are one of many tools investors use to make informed decisions, and the 13F filings are backward-looking, reflecting past positions that may have changed since.